Markers of Osteoporosis in Cystic Fibrosis

Description

Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.

Conditions

Cystic Fibrosis

Study Overview

Study Details

Study overview

Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.

Markers of Osteoporosis in Cystic Fibrosis

Markers of Osteoporosis in Cystic Fibrosis

Condition
Cystic Fibrosis
Intervention / Treatment

-

Contacts and Locations

Dallas

UT Southwestern Medical Center, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Must have CF diagnosis confirmed by sweat test or genotype analysis
  • * Subjects (and parents/legal guardians as applicable) must have the ability to read and write in English
  • * No CF diagnosis
  • * Men or women without osteoporosis
  • * Less than 18 years of age
  • * Unwilling to return annually for study visits for up to 5 years
  • * Unwilling and/or medically unable to take denosumab

Ages Eligible for Study

18 Years to 64 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Texas Southwestern Medical Center,

Study Record Dates

2027-07